A Phase 3 interventional study of Ragweed Pollen Skin Prick Test Solution (3,500 DU/mL) and Dog Dander Skin Prick Test Solution (19,500 DU/mL) in Allergic Disorder, sponsored by Zhejiang Wolwo Bio-Pharmaceutical Co., Ltd.. Not yet recruiting at 3 sites in China. Open to participants aged 18 Years to 60 Years. Per ClinicalTrials.gov, last updated 2026-11-18.
Sponsored by Zhejiang Wolwo Bio-Pharmaceutical Co., Ltd. · Phase 3, Interventional, and Diagnostic
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 35 studies in Hypersensitivity with a site in China — 9 open to participants now, 9 under way, 1 of them phase 3. Hypersensitivity · China.
Among the 35 studies in Hypersensitivity with a site in China, this one is the 3rd largest by planned enrollment of the 20 interventional ones that give a count, is one of 6 that started in 2026, is one of 5 in phase 3, and was the 35th registered.
1,059 studies on the registry are indexed under Hypersensitivity; 152 are open to participants now.
Browse Hypersensitivity studies →9 of the 35 studies in Hypersensitivity with a site in China are open now. Recruiting first, the newest first:
Qifeng Zhang · Sites in China, United States
Bo Wang,MD · Sites in China
Ages 18+
Min-Tze LIONG · Sites in China, Malaysia
Ages 0 mo–36 mo · Healthy volunteers
The First Affiliated Hospital with Nanjing Medical University · Sites in China
Ages 14–90
Women's Hospital School Of Medicine Zhejiang University · Sites in China
Ages 25–70 · Women only · Healthy volunteers
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 101 Hypersensitivity studies recruiting now, 38 (38%) set no upper age limit and 51 (50%) stop at 75 or younger; 55 take children under 18; 37 take healthy volunteers.
This study: 18 Years to 60 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
35 studies; the count open now beside each. This study's row is marked.
First in 2006; this study’s year is marked. 6 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 650 is above the median of 73 across 693 interventional studies indexed under Hypersensitivity.
Median enrollment 200 across the 20 interventional studies, 180 across the 15 observational. Of the 19 that completed or were terminated, 1 (5%) have results posted.
This tab as a report to print or save as PDF → With an account.
12 of 35 have an industry lead sponsor. The 10 most frequent:
Zhejiang Wolwo Bio-Pharmaceutical Co., Ltd. is the lead sponsor of 2 studies on the registry; 2 are open to participants now.
Zhejiang Wolwo Bio-Pharmaceutical Co., Ltd. has 1 study filed under Hypersensitivity — fewer than ten, so there is no comparison to draw.
1 of the studies in Hypersensitivity with a site in China that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07945665Phase 3Zhejiang Wolwo Bio-Pharmaceutical Co., Ltd.Diagnostic Performance and Safety of Ragweed Pollen and Dog Dander Skin Prick Test Solutions | 2027-06-01 |
Add it to your calendar (.ics) → With an account.
Among the 35 studies in Hypersensitivity with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This multicenter, open-label, Phase III interventional study will evaluate the diagnostic performance and safety of ragweed pollen and dog dander skin prick test (SPT) solutions in adults in China with current or previous allergic diseases. Participants will undergo serum allergen-specific immunoglobulin E (sIgE) testing using the Thermo Fisher Scientific ImmunoCAP system. Each enrolled participant will receive one skin prick with ragweed pollen solution (3,500 DU/mL), dog dander solution (19,500 DU/mL), dog dander solution (39,000 DU/mL), and positive and negative controls. Wheal responses will be assessed 15-20 minutes after skin pricking. Diagnostic sensitivity and specificity will be determined separately for each test solution against the corresponding serum sIgE classification (cutoff ≥0.70 kUA/L). Safety will be assessed through adverse events, symptoms, vital signs, physical examinations, and laboratory tests.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
All enrolled participants receive ragweed pollen SPT solution (3,500 DU/mL), dog dander SPT solution (19,500 DU/mL), dog dander SPT solution (39,000 DU/mL), and positive and negative control solutions during the same test session.
Diagnostic Test: Ragweed Pollen Skin Prick Test Solution (3,500 DU/mL) · Diagnostic Test: Dog Dander Skin Prick Test Solution (19,500 DU/mL) · Diagnostic Test: Dog Dander Skin Prick Test Solution (39,000 DU/mL)
One drop applied to the volar forearm, followed by a single skin prick; wheal assessed 15-20 minutes later.
One drop applied to the volar forearm, followed by a single skin prick; wheal assessed 15-20 minutes later.
One drop applied to the volar forearm, followed by a single skin prick; wheal assessed 15-20 minutes later.
Sensitivity: Ragweed Pollen (3,500 DU/mL)
Percentage of participants with a positive SPT result among participants with serum ragweed sIgE ≥0.70 kUA/L by ImmunoCAP (w1). An SPT is positive when maximum wheal diameter is ≥3 mm, provided control validity criteria are met.
Time frame: 15-20 minutes after skin prick testing (Day 1).
Specificity: Ragweed Pollen (3,500 DU/mL)
Percentage of participants with a negative SPT result among participants with serum ragweed sIgE \<0.70 kUA/L by ImmunoCAP (w1). An SPT is negative when maximum wheal diameter is \<3 mm, provided control validity criteria are met.
Time frame: 15-20 minutes after skin prick testing (Day 1).
Sensitivity: Dog Dander (19,500 DU/mL)
Percentage of participants with a positive SPT result among participants with serum dog dander sIgE ≥0.70 kUA/L by ImmunoCAP (e5). An SPT is positive when maximum wheal diameter is ≥3 mm, provided control validity criteria are met.
Time frame: 15-20 minutes after skin prick testing (Day 1).
Specificity: Dog Dander (19,500 DU/mL)
Measure Description: Percentage of participants with a negative SPT result among participants with serum dog dander sIgE \<0.70 kUA/L by ImmunoCAP (e5). An SPT is negative when maximum wheal diameter is \<3 mm, provided control validity criteria are met.
Time frame: 15-20 minutes after skin prick testing (Day 1).
Sensitivity: Dog Dander (39,000 DU/mL)
Percentage of participants with a positive SPT result among participants with serum dog dander sIgE ≥0.70 kUA/L by ImmunoCAP (e5). An SPT is positive when maximum wheal diameter is ≥3 mm, provided control validity criteria are met.
Time frame: 15-20 minutes after skin prick testing (Day 1).
Specificity: Dog Dander (39,000 DU/mL)
Percentage of participants with a negative SPT result among participants with serum dog dander sIgE \<0.70 kUA/L by ImmunoCAP (e5). An SPT is negative when maximum wheal diameter is \<3 mm, provided control validity criteria are met.
Time frame: 15-20 minutes after skin prick testing (Day 1).
Adverse Events
Number and percentage of participants experiencing adverse events, adverse drug reactions, serious adverse events, serious adverse drug reactions, and adverse events leading to withdrawal, by test solution as applicable.
Time frame: From first skin prick administration (Day 1) through the final study visit (approximately 24 hours +4 hours after testing), with follow-up of unresolved events as required by protocol.
Changes in Vital Signs from Baseline
Changes in vital signs from baseline will be assessed, including body temperature (°C), systolic and diastolic blood pressure (mmHg), and pulse rate (beats/min). Descriptive statistics, including mean, median, standard deviation, quartiles, minimum, and maximum, will be presented.Changes in vital signs will be summarized using cross-tabulations. Clinically significant abnormalities will be listed.
Time frame: At screening, within 2 hours before SPT, 1 hour ±10 minutes after SPT, and 24 hours ±4 hours after SPT.
Changes in Physical Examination Findings from Baseline
Changes in physical examination findings from baseline will be assessed, including skin and mucosa, lymph nodes, head and neck, chest, abdomen, and spine and extremities. Changes in examination findings will be summarized using cross-tabulations. Clinically significant abnormalities will be listed.
Time frame: At screening and on Day 2 of the study or at early termination.
Changes in Hematology Parameters from Baseline
Changes in hematology parameters from baseline will be assessed, including white blood cell count; absolute and percentage counts of neutrophils, lymphocytes, monocytes, eosinophils, and basophils; red blood cell count; hemoglobin; and platelet count. Units of measurement will follow the laboratory reports. Quantitative results will be summarized using the mean, median, standard deviation, quartiles, minimum, and maximum. Changes in clinical assessment categories will be summarized using cross-tabulations. Clinically significant abnormalities will be listed.
Time frame: At screening and on Day 2 of the study or at early termination.
Changes in Urinalysis Parameters from Baseline
Changes in urinalysis parameters from baseline will be assessed, including urine bilirubin, glucose, ketones, protein, occult blood, and leukocytes or leukocyte esterase. Results will be summarized according to the categories reported by the laboratory. Changes in results will be summarized using cross-tabulations. Clinically significant abnormalities will be listed.
Time frame: At screening and on Day 2 of the study or at early termination.
Start is estimated for Nov 2026; primary completion for Jun 2027, 6 months later.
Of 32 industry-sponsored phase 3 interventional studies under Hypersensitivity, half reached primary completion within 20 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 34. This study's planned 6 months is below that.
Counting every sponsor, half of 42 studies reached it within 23 months; a quarter within 10 and three quarters within 34.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Zhejiang Wolwo Bio-Pharmaceutical Co., Ltd.